September 13, 2019 — Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.
During the meeting, attendees will have the opportunity to learn about the mounting body of clinical evidence illustrating the expanding use of Cesium-131, now known as Cesium Blu, and its effectiveness in treating recurrent brain cancers including meningiomas and brain metastases.
Attendees will also get a first-hand look at the Blu Build real-time Cesium-131 internal radiation therapy delivery system. Blu Build is believed to be the first new delivery system in years designed specifically for prostate internal radiation therapy, according to the company. The delivery system enables doctors to deliver a high radiation dose to the targeted prostate cancer and limits the impact on the surrounding areas compared to other treatment options.
Isoray representatives will be at the company’s booth to discuss recent developments with attendees regarding clinical applications where Cesium-131 has been found to be a potent, valuable option for clinicians and their patients.
For more information: www.isoray.com
October 19, 2026 
